ACIU
$3.32
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Intraday
Recent News
AC Immune: Q4 Earnings Snapshot
LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Friday reported a loss of $18 million in its fourth quarter. The Lausanne, Switzerland-based company said it had a loss of 18 cents per share. The biopharmaceutical company posted revenue of $423,000 in the period.
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial.
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0
Top Penny Stocks To Watch In January 2026
As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in...
Retail investors are AC Immune SA's (NASDAQ:ACIU) biggest owners and were rewarded after market cap rose by US$53m last week
Key Insights AC Immune's significant retail investors ownership suggests that the key decisions are influenced by...